Hansoh Pharmaceutical Group Company Limited
3692
株式のランク
#904
Hansoh Pharmaceutical Group Company Limited, an investment holding company,... Hansoh Pharmaceutical Group Company Limited, an investment holding company, engages in the research, development, production, and sale of pharmaceutical products in the People’s Republic of China. The company provides products for therapeutic areas, including anti-infection, central nervous system, oncology, and metabolic and other diseases, as well as autoimmune diseases. Its principal products include Ameile, Hansoh Xinfu, Pulaile, Zefei, Xintai, Xinmei, Gainuo, Tanneng, and Pulaitan; Hengmu, Mailingda, Hengsen, Oulanning, Ailanning, and Ameining; XINYUE; and Saint Luolai, Fulaimei, Ruibote, Fulaidi, Fulairui, Punuoan tablets, etc. It has licence agreements with GlaxoSmithKline Intellectual Property (No.4) Limited to develop, manufacture, and commercialize HS-20089 and HS-20093 for the treatment of patients with extensive-stage small-cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy; Biotheus Inc. to develop, produce, and commercialize bispecific antibody-drug conjugate product; and with Merck Sharp & Dohme LLC (MSD) to develop, manufacture, and commercialize HS-10535, an investigational pre-clinical oral small molecule glucagon-like peptide-1 (GLP-1) receptor agonist. The company was founded in 1995 and is headquartered in Shanghai, China. Hansoh Pharmaceutical Group Company Limited is a subsidiary of Stellar Infinity Company Ltd.
株価
$4.40
時価総額
$26.66B
変化（1日）
0.00%
変化（1年）
-4.79%
国
CN
取引 Hansoh Pharmaceutical Group Company Limited (3692)
カテゴリー
Healthcare
Hansoh Pharmaceutical Group Company Limited（3692）のP/B比率
October 2026 時点のP/B比率 TTM: 4.30
Hansoh Pharmaceutical Group Company Limited の最新の財務報告および株価によると、現在のP/B比率（TTM）は 4.30 です。2023 年末時点でのP/B比率は 3.47 でした。
Hansoh Pharmaceutical Group Company Limited の P/B 比率の履歴（2016 ～ 2026）
各年末時点のP/B比率
| 年 | P/B比率 | 変化 |
|---|---|---|
| 2026 (TTM) | 4.30 | 28.00% |
| 2024 | 3.36 | -3.35% |
| 2023 | 3.47 | 1.44% |
| 2022 | 3.42 | -25.17% |
| 2021 | 4.57 | -56.01% |
| 2020 | 10.40 | 7.03% |
| 2019 | 9.72 | -86.95% |
| 2018 | 74.45 | 213.64% |
| 2017 | 23.74 | -55.98% |
| 2016 | 53.92 | 0.00% |
同業他社のP/B比率
| 企業 | P/B比率 | P/B比率の差 | 国 |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| 5.041 | 17.21% |
IN
|
